Corcept Therapeutics (CORT) Tops Q2 EPS by 2c; Offers FY22 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. ANET
6. DUOL
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Corcept Therapeutics (CORT) Tops Q2 EPS by 2c; Offers FY22 Revenue Guidance

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

August 3, 2022 4:05 PM EDT

MENLO PARK, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2022.

Financial Results

Revenue of $103.4 million, compared to $91.6 million in second quarter 2021Reiterated 2022 revenue guidance of $400 $430 millionDiluted net income per... More